Table 12.
Vaccine | Vector | Dosage | Price | Vaccination ages |
Immunity | Contraindication | Ref. |
---|---|---|---|---|---|---|---|
Bovilis (Intervet, The Netherlands) |
Inactivated BVD virus | Two 2-ml doses im. 4 weeks apart with annual revaccination with single dose |
US$21/25 doses (US$0.84/ dose) |
8 months | Reduced viral excretion and neutralizing antibodies |
fetal protection can be achieved if administered 4 weeks before start of gestation Should not be administered within 21 days to slaughter |
[102] |
Breed-back™ FP 10 (Boehringer- Ingelheim, UK) |
BVD Types 1 and 2, MLV, IBR, PI3 and BRSV, MLV with adjuvant |
Two 2-ml doses sc. 14–28 days apart with annual revaccination with single dose |
US$9.75/five doses (US$1.95/ dose) |
No age restriction, but calves vaccinated before 6 months of age should be revaccinated after 6 months of age |
91–100% protection from fetal infection, 14/22 calves free of clinical signs |
Should not be vaccinated within 21 days before slaughter Should not use in pregnant cows or in calves nursing pregnant cows |
[103] |
DNA vaccine (Liang et al. 2008) |
Plasmid encoding a truncated secreted version of E2 with a tissue plasminogen activator signal sequence, followed by boosting with E2 protein formulated with 10% Emulsigen, a mineral oil in water emulsion, and CpG oligodeoxynucleotide |
1 mg of DNA delivered transdermally via needle-free injection, followed by 50 µg of protein |
Unknown | 8–9 months | Virus-neutralizing antibodies and INF-γ-producing CD4+T cells, reducing leucopenia, no weight loss or temperature response |
Unknown | [100] |
DNA vaccine (Nobiron et al. 2003) |
Plasmid expressing E2 glycoprotein of BVDV |
500 µg DNA intradermally |
Unknown | 3–7 months | Low levels of neutralizing antibodies, elevated T-cell proliferation, reduced febrile responses |
Unknown | [101] |
BRSV: Bovine respiratory synctitial virus; BVD: Bovine virus diarrhea; BVDV: Bovine virus diarrhea vaccine; IBR: Infectious bovine rhinotracheitis; im.: Intramuscular; MLV: Modified live virus; PI3: Parainfluenza type-3; sc.: Subcutaneous.